Improved sensitivity and specificity for citrin deficiency using selected amino acids and acylcarnitines in the newborn screening

• Published in: Journal of inherited metabolic disease
• Main Authors: Kido, Jun, Häberle, Johannes, Tanaka, Toju, Nagao, Masayoshi, Wada, Yoichi, Numakura, Chikahiko, Bo, Ryosuke, Nyuzuki, Hiromi, Dateki, Sumito, Maruyama, Shinsuke, Murayama, Kei, Yoshida, Shinichiro, Nakamura, Kimitoshi
• Format: Journal Article
• Language: English
• Published: 12.09.2023
• ISSN: 0141-8955; 1573-2665
• DOI: 10.1002/jimd.12673

Abstract Citrin deficiency is an autosomal recessive disorder caused by a defect of citrin resulting from mutations in the SLC25A13 gene. Intrahepatic cholestasis and various metabolic abnormalities, including hypoglycemia, galactosemia, citrullinemia, and hyperammonemia may be present in neonates or infants in the “neonatal intrahepatic cholestasis caused by citrin deficiency” (NICCD) form of the disease. Because at present, newborn screening (NBS) for citrin deficiency using citrulline levels in dried blood spots (DBS) can only detect some of the patients, we tried to develop a new evaluation system to more reliably detect newborns with citrin deficiency utilizing parameters already in place in present NBS methods. To achieve this goal, we re‐analyzed NBS profiles of amino acids and acylcarnitines in 96 NICCD patients, who were diagnosed through selective screening or positive family history. Hereby, we identified the combined evaluation of arginine (Arg), citrulline (Cit), isoleucine+leucine (Ile + Leu), tyrosine (Tyr), free carnitine (C0) / glutarylcarnitine (C5‐DC) ratio in DBS as potentially sensitive to diagnose citrin deficiency in pre‐symptomatic newborns. In particular, a scoring system using threshold levels for Arg (≥9 μmol/L), Cit (≥ 39 μmol/L), Ile + Leu (≥ 99 μmol/L), Tyr (≥ 96 μmol/L) and C0/C5‐DC ratio (≥327) was significantly effective to detect newborns who later developed NICCD, and could thus be implemented in existing NBS programs at no extra analytical costs whenever citrin deficiency is considered to become a novel target disease.